What Is Survodutide?
Survodutide is a once-weekly injectable GLP-1 and glucagon receptor dual agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma. Like mazdutide and the glucagon-targeting component of retatrutide, it combines GLP-1's appetite suppression with glucagon's fat-burning and energy expenditure effects.
The MASH Opportunity
One of the most significant aspects of survodutide's pipeline is its investigation for metabolic-associated steatohepatitis (MASH), previously known as NASH. MASH is a progressive liver disease closely linked to obesity and metabolic syndrome, with very limited treatment options. Survodutide's combination of fat-burning (via glucagon) and metabolic improvement (via GLP-1) creates a plausible mechanism for liver benefit beyond what weight loss alone provides.
Phase 2 Results
Phase 2 results published in 2024 showed survodutide producing meaningful weight loss with an acceptable safety profile, sufficient to support advancement into Phase 3 trials for both obesity and MASH.
Current Status
As of 2026, survodutide is in Phase 3 trials for obesity and MASH. If approved for MASH, it could represent an important treatment option for a condition that currently has very few effective pharmaceutical interventions.